Zymeworks, Inc.
1385 West 8th Avenue
Suite 540
Vancouver
British Columbia
V6H 3V9
Canada
Tel: 604-678-1388
Website: http://www.zymeworks.com/
Email: info@zymeworks.com
About Zymeworks, Inc.
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
281 articles about Zymeworks, Inc.
-
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
1/19/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
-
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
1/15/2022
Zymeworks Inc. reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08, an equity inducement award to Mr. Kenneth Galbraith, Zymeworks’ new Chair, President and Chief Executive Officer.
-
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference.
-
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
1/5/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer of Zymeworks, effective on or before February 1, 2022.
-
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
12/9/2021
Zymeworks Inc. today announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON‑GEA‑01 trial.
-
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
12/8/2021
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer.
-
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
12/1/2021
Zymeworks Inc. today announced that Janssen Biotech, Inc. (“Janssen”) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
-
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
11/9/2021
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
-
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
11/9/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Neil Josephson, M.D., who has been serving as the company’s interim Chief Medical Officer since May of this year, will transition to the permanent CMO position, effective November 15.
-
Zymeworks to Present at Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will participate in three upcoming investor conferences.
-
Zymeworks Reports 2021 Third Quarter Financial Results
11/3/2021
Zymeworks Inc. today reported financial results for the third quarter ended September 30, 2021.
-
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
10/26/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers.
-
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
10/5/2021
Zymeworks Inc. and ALX Oncology Holdings Inc. today announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
9/16/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA.
-
The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.
-
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
9/12/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA.
-
Zymeworks Reports 2021 Second Quarter Financial Results
8/4/2021
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the second quarter ended June 30, 2021.
-
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
8/3/2021
Zymeworks Inc. today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
-
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
7/28/2021
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease.